Pulmonary Arterial Hypertension

10/25/2017 - "Prostacyclin pathway medications have been shown to be highly efficacious in the treatment of pulmonary arterial hypertension (PAH) through multiple prospective clinical trials and more than two decades of clinical experience. "
02/15/2003 - "Epoprostenol has markedly improved the treatment of pulmonary arterial hypertension, although predictors of outcome with epoprostenol are not well characterized. "
01/01/2023 - "Intravenous (i.v.) prostacyclin is the cornerstone treatment in high-risk pulmonary arterial hypertension (PAH) patients. "
01/01/2018 - "Investigation of safety and efficacy of the new more thermostable formulation of Flolan (epoprostenol) in Japanese patients with pulmonary arterial hypertension (PAH)-An open-label, single-arm study."
01/01/2019 - "Prostacyclin mimetics (PMs) are effective for the treatment of pulmonary arterial hypertension (PAH). "

05/13/2014 - "The double-blind, placebo-controlled Sildenafil in Treatment-Naive Children, Aged 1 to 17 Years, With Pulmonary Arterial Hypertension (STARTS-1) study assessed sildenafil in pediatric patients with pulmonary arterial hypertension; improved hemodynamics and exercise capacity occurred in medium- and high-dose groups. "
02/01/2008 - "After increasing the sildenafil dose to ensure therapeutic drug levels over 24 hours, the pulmonary arterial hypertension and physical performance of the patient improved significantly. "
04/20/2005 - "Sildenafil use in children appears to be safe and may be beneficial in the management of pulmonary arterial hypertension."
01/01/2012 - "Sildenafil has been demonstrated as effective for the treatment of pulmonary arterial hypertension (PAH). "
02/15/2011 - "Sildenafil has been shown to be effective in pulmonary arterial hypertension (PAH). "

10/01/2004 - "Bosentan (Tracleer), Actelion), has proven effective in clinical trials, and is the most frequently used pulmonary arterial hypertension-specific agent worldwide. "
06/21/2008 - "Bosentan treatment could be beneficial for patients with WHO FC II pulmonary arterial hypertension."
04/01/2003 - "This study was conducted to investigate the pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. "
07/01/2011 - "Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children."
12/01/2010 - "Bosentan and improved pulmonary endothelial function in pulmonary arterial hypertension."

01/01/2017 - "In addition, the improved local availability resulted in better pharmacological efficacy in a monocrotaline-induced rat model of pulmonary arterial hypertension. "
10/01/2013 - "By in vivo experiments, we showed for the first time female bone marrow-derived mesenchymal stem cells possessed a better therapeutic potential against monocrotaline-induced pulmonary arterial hypertension in C57BL/6J mice compared with male counterparts. "
01/01/2021 - "In the present study, the therapeutic efficacy of a selective BKCa channel opener (compound X) in the treatment of monocrotaline (MCT)-induced pulmonary arterial hypertension (PAH) was investigated. "
07/30/2013 - "Therapeutic efficacy of AAV1.SERCA2a in monocrotaline-induced pulmonary arterial hypertension."
07/01/2017 - "The protective effects of PCPA against monocrotaline-induced pulmonary arterial hypertension are mediated through the downregulation of NFAT-1 and NF-κB."

01/01/2021 - "To evaluate the efficacy of endothelin receptor antagonists (ERAs) in pulmonary arterial hypertension. "
06/01/2016 - "Endothelin receptor antagonists (ERAs) have been shown to improve the prognosis of patients with pulmonary arterial hypertension (PAH). "
03/01/2016 - "Endothelin receptor antagonists have been shown to improve exercise tolerance and survival in adult patients with pulmonary arterial hypertension. "
02/28/2013 - "To evaluate the efficacy of endothelin receptor antagonists in pulmonary arterial hypertension. "
07/08/2009 - "To evaluate the efficacy of endothelin receptor antagonists in pulmonary arterial hypertension. "

11/01/2023 - "EXPEDITE (NCT03497689), a single-arm, multicenter study, assessed the efficacy of rapid parenteral treprostinil induction to quickly reach higher doses of oral treprostinil for the treatment of pulmonary arterial hypertension. "
04/12/2023 - "Overall, the results indicate that the developed drug in the adhesive patch can effectively deliver treprostinil through the skin and could be a promising treatment option for pulmonary arterial hypertension."
12/01/2012 - "Infused and inhaled treprostinil are effective for treatment of pulmonary arterial hypertension (PAH), although their administration routes have limitations. "
01/01/2008 - "Subcutaneous treprostinil is an effective treatment for pulmonary arterial hypertension (PAH). "
03/01/2006 - "Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial."

01/01/2022 - "The earliest clinical studies of prostanoid treatment in pulmonary arterial hypertension demonstrated an important link between lowering mean pulmonary arterial pressure (or pulmonary vascular resistance) and improved survival. "
01/01/2020 - "Prostanoid treatment in patients with severe pulmonary arterial hypertension (PAH) has been proven safe and effective. "
04/01/2020 - "Parenteral prostanoids are effective for improving outcomes in patients with pulmonary arterial hypertension. "
07/01/2007 - "Prostanoids have been shown to improve exercise tolerance, hemodynamics and quality of life in patients with pulmonary arterial hypertension (PAH). "
12/01/2005 - "In pulmonary arterial hypertension, prostanoid inhalation has been found to improve pulmonary hemodynamics, right ventricular function, gas exchange, and clinical outcome. "

05/01/2008 - "Inhaled iloprost is an effective treatment for NYHA class III pulmonary arterial hypertension, either idiopathic primary or associated with a particular condition, such as scleroderma. "
11/21/2023 - "The efficacy of iloprost in treating pulmonary arterial hypertension (PAH) is controversial. "
01/01/2017 - "There are few published data on the efficacy of i.v. iloprost in pulmonary arterial hypertension (PAH). "
03/01/2011 - "Clinical pharmacology and efficacy of inhaled iloprost for the treatment of pulmonary arterial hypertension."
07/01/2009 - "There is limited data on the long-term efficacy of intravenous iloprost in patients with pulmonary arterial hypertension (PAH). "

11/01/2010 - "As new selective pulmonary vasodilators have become available and proven to be beneficial in various forms of pulmonary arterial hypertension, this targeted medical treatment has been expected to show promising effects with a delay of deterioration also in Eisenmenger patients. "
11/01/2010 - "As new selective pulmonary vasodilators have become available and proven to be beneficial in various forms of pulmonary arterial hypertension, this targeted medical treatment has been expected to show promising effects with a delay of deterioration also in Eisenmenger patients. "
11/01/2010 - "As new selective pulmonary vasodilators have become available and proven to be beneficial in various forms of pulmonary arterial hypertension, this targeted medical treatment has been expected to show promising effects with a delay of deterioration also in Eisenmenger patients. "
05/01/2020 - "The prognosis of pulmonary arterial hypertension (PAH) has significantly improved over the past two decades due to advances in medications, including pulmonary vasodilators. "
11/01/2022 - "Although pulmonary vasodilators have been effective in treating patients with a pulmonary vasculopathy, such as pulmonary arterial hypertension (PAH), these results have not been replicated in those with PH-HFpEF. "

01/01/2016 - "In this study we evaluated the safety and efficacy of oral tadalafil in children with pulmonary arterial hypertension (PAH). "
08/21/2012 - "In the multicenter, placebo-controlled, randomized, 16-week PHIRST (Pulmonary Arterial Hypertension and Response to Tadalafil) study, tadalafil 40 mg improved exercise capacity and delayed clinical worsening. "
08/21/2012 - "The aim of this study was to evaluate the long-term safety and durability of efficacy of tadalafil for pulmonary arterial hypertension. "
03/01/2014 - "There are limited data on the management of pulmonary arterial hypertension (PAH) in the elderly; therefore, this analysis compared the safety and efficacy of tadalafil between patients ≥65 and <65 years old. "
06/09/2009 - "In patients with pulmonary arterial hypertension, tadalafil 40 mg was well tolerated and improved exercise capacity and quality of life measures and reduced clinical worsening."

01/01/2013 - "The 6-Minute Walk Distance (6-MWD) has been the most utilized endpoint for judging the efficacy of pulmonary arterial hypertension (PAH) therapy in clinical trials conducted over the past two decades. "
05/09/2021 - "Pulmonary arterial hypertension (PAH)-specific therapy has improved pulmonary hemodynamics at rest; however, the pulmonary hemodynamic response to exercise is still abnormal in most patients with PAH. "
10/01/2020 - "Several pulmonary arterial hypertension-targeted therapies have become available to reduce pulmonary artery pressure and improve outcome, but there is still no cure for most patients. "
01/01/2012 - "Recently studied therapies for pulmonary arterial hypertension (PAH) have improved outcomes among populations of patients, but little is known about which patients are most likely to respond to specific treatments. "
06/01/2015 - "Pulmonary arterial hypertension (PAH) and CTEPH have similar clinical presentations and histopathological features, so agents shown to be effective in PAH have often been prescribed to patients with CTEPH in the absence of proven therapies. "

05/01/2019 - "This qualitative systematic review is conducted to evaluate the safety and efficacy of pulmonary arterial hypertension-specific drug therapy (PAH-SDT) for ES patients for a clinical therapeutic strategy based on evidence. "
11/01/2018 - "As drug therapy is not expected to offer relief from the mechanical obstructions of pulmonary arteries and the use of specific pulmonary arterial hypertension drugs is not established in thalassaemia patients, the novel technique of balloon pulmonary angioplasty (BPA) may emerge as a new therapeutic option for patients with inoperable CTEPH and thalassaemia. "
10/19/2021 - "For pulmonary arterial hypertension, a disease once characterized by a particularly grim prognosis, prospective randomized drug trials with aggressive single (or combined) pharmacotherapy have measurably improved survival and quality of life for many patients. "
01/01/2020 - "Aim: No network meta-analysis has been conducted to study efficacy of drug therapies specific for treatment of pulmonary arterial hypertension in treatment-naive patients only. "
01/01/2019 - "Towards improved pharmacotherapy in pulmonary arterial hypertension. "

12/12/2022 - "Pulmonary Artery Denervation: A New Therapeutic for Pulmonary Arterial Hypertension?"
11/01/2015 - "Pulmonary artery denervation offers the possibility of a new treatment option for patients with pulmonary arterial hypertension. "
12/12/2022 - "(Safety and Efficacy of Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension [PADN-CFDA]; NCT03282266)."
01/01/2023 - "Treatment effects of pulmonary artery denervation for pulmonary arterial hypertension stratified by REVEAL risk score: Results from PADN-CFDA trial."
03/01/2022 - "This study aimed to assess the long-term effects of pulmonary artery denervation (PADN) on mortality in patients with pulmonary arterial hypertension (PAH). "

10/01/2023 - "This review focuses on the complexities of lung transplantation for patients with pulmonary arterial hypertension, presents the updated referral and listing criteria, and discusses the inequities in the organ allocation process that impact this disease group and the strategies to optimize outcomes for patients with pulmonary arterial hypertension who require lung transplantation. "
10/01/2023 - "In patients with end-stage pulmonary arterial hypertension, lung transplantation has the potential both to extend survival and improve health-related quality of life. "
10/01/2023 - "Lung Transplantation for Pulmonary Arterial Hypertension."
08/15/2023 - "Lung Transplantation for Pulmonary Arterial Hypertension: Optimized Referral and Listing Based on an Evolving Disease Concept."
01/01/2023 - "Bilateral lung transplantation (LuTx) remains the only established treatment for children with end-stage pulmonary arterial hypertension (PAH). "

01/01/2012 - "Although transplantation of adult bone marrow mesenchymal stem cells (BM-MSCs) holds promise in the treatment for pulmonary arterial hypertension (PAH), the poor survival and differentiation potential of adult BM-MSCs have limited their therapeutic efficiency. "
03/01/2008 - "Autologous bone marrow-derived endothelial progenitor cell transplantation effectively ameliorates MCT-induced pulmonary arterial hypertension."
10/01/2023 - "Sadly, patients with pulmonary arterial hypertension face many challenges as it relates to transplantation including higher perioperative risks, inequities in the allocation system, and less favorable long-term outcomes. "
10/01/2023 - "Pulmonary arterial hypertension is the only major diagnostic indication for transplantation that is not a parenchymal pulmonary process, and thus the care of these patients is unique. "
01/01/2022 - "Transplantation of viable mitochondria improves right ventricular performance and pulmonary artery remodeling in rats with pulmonary arterial hypertension."